{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:08:55Z","timestamp":1789574935608,"version":"build-2803163510"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed\/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these challenges ask for new approaches to optimize treatment and to eventually understand resistance mechanisms. This phase 1 study (NCT04557150) investigated mode of action and resistance mechanisms of forimtamig, a novel GPRC5DxCD3 TCB. Biomarker analyses included deep phenotyping of patients' tumor and immune cells, functional T cell characterization, cytokine release, soluble B-cell maturation antigen kinetics and minimal residual disease evaluation. Biomarker data analysis assessed the impact of different TCB treatment approaches on T cell-mediated tumor killing dynamics: subcutaneous vs intravenous administration, weekly vs every 4 days step-up dosing, and low vs high target doses. A machine learning model revealed T-to-natural killer (NK)cell ratio in blood and bone marrow as a strong predictor of response. Single cell transcriptomics showed increased DNA repair and proliferation as major tumor hallmarks associated with resistance, while T cell dysfunction signatures were not predictive of response. T cells from non-responding patients showed an increased cytokine release when exposed to higher forimtamig exposure in an ex vivo setting. T cells from responding and non-responding patients were equally fit in killing tumor cells ex vivo. Our results highlight that forimtamig treatment optimization may be possible by boosting T cell numbers over NK cells, targeting tumor intrinsic resistance mechanisms or individualized dosing approach.<\/jats:p>","DOI":"10.1182\/bloodadvances.2026020503","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:41:19Z","timestamp":1789573279000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["T-cell dynamics, CD8\/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma"],"prefix":"10.1182","author":[{"given":"Iryna","family":"Dekhtiarenko","sequence":"first","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2159-2880","authenticated-orcid":false,"given":"Jan","family":"Attig","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-0689","authenticated-orcid":false,"given":"Iva","family":"Lelios","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-2931","authenticated-orcid":false,"given":"Stephan","family":"Schmeing","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen SM","family":"Yong","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-7542","authenticated-orcid":false,"given":"Wolfgang","family":"Jacob","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich, pRED, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-2690","authenticated-orcid":false,"given":"Emilio","family":"Y\u00e1ng\u00fcez","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-8852","authenticated-orcid":false,"given":"Tamara","family":"H\u00fcsser","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llucia","family":"Albert\u00ed Servera","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4291-8584","authenticated-orcid":false,"given":"Inga","family":"Clausen","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Grote","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich, pRED, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia S.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-2398","authenticated-orcid":false,"given":"Hans-Joachim","family":"Helms","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-2707","authenticated-orcid":false,"given":"Cristina","family":"Santini","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4654-1131","authenticated-orcid":false,"given":"Emilie","family":"Schindler","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, pRED, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-696X","authenticated-orcid":false,"given":"Sylvia","family":"Herter","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0581-9579","authenticated-orcid":false,"given":"Marina","family":"Bacac","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich, Roche Pharma Research and Early Development (pRED), Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"Humanitas University and IRCCS Humanitas Research Hospital, Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Caroline","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"CHU de Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori \"Fondazione G Pascale\", IRCCS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Nazionale dei Tumori, University of Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine, Korea, Republic of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weisser","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich, pRED, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie E.","family":"Br\u00f6ske","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Munich, pRED, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,16]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020503\/2589469\/bloodadvances.2026020503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020503\/2589469\/bloodadvances.2026020503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:41:19Z","timestamp":1789573279000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026020503\/570968\/T-cell-dynamics-CD8-NK-ratio-and-tumor-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020503","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"bloodadvances.2026020503"}}